Search

Displaying results 2611 - 2620 of 2955 in total
  1. Drug

    Crinecerfont

    go.drugbank.com/drugs/DB18518
    ApprovedInvestigational

    [A264818] Crinecerfont was approved by the FDA in December 2024 as an adjunct to glucocorticoid replacement in patients with CAH.[L51973,L51993]

  2. Drug

    Daraxonrasib

    go.drugbank.com/drugs/DB22308
    ApprovedInvestigational

    [L64039,L64040] The FDA approved daraxonrasib on August 26, 2026 for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are

  3. Drug

    Otilimab

    go.drugbank.com/drugs/DB06303
    Investigational

    Investigated for the treatment of osteoarthritis and rheumatoid arthritis (RA).

  4. Drug

    Sufentanil

    go.drugbank.com/drugs/DB00708
    ApprovedInvestigational

    Sufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. It is administered by the intravenous, epidural and sublingual routes. Also known as Dsuvia, the subli...

  5. Drug

    SBT-100

    go.drugbank.com/drugs/DB17215
    Experimental

    It was granted orphan drug designation by the FDA for the treatment of pancreatic cancer and osteosarcoma.[L44131,L44136]

  6. Drug

    Coal tar

    go.drugbank.com/drugs/DB11082
    Approved

    Coal tar is a brown or black liquid of extremely high viscosity. Coal tar is among the by-products when coal is carbonized to make coke or gasified to make coal gas. Coal tars are complex and variable mixtures of phenols, polycyclic arom...

    Mixtures: PREPARED COAL TAR 5% ET SALICYLIC ACID 2% OINTMENT
  7. Drug

    Chikungunya vaccine (live, attenuated)

    go.drugbank.com/drugs/DB18701
    ApprovedInvestigational

    [L48731] Chikungunya vaccine (live, attenuated) - marketed under the name Ixchiq - was approved by the FDA in November 2023, becoming the first and only vaccine indicated for the prevention of disease

  8. Drug

    Efanesoctocog alfa

    go.drugbank.com/drugs/DB16662
    ApprovedInvestigational

    [A257464,A257469] In February 2023, efanesoctocog alfa was approved by the FDA as a new class of factor VIII therapy for hemophilia A.[L45379,L45414]

  9. Drug

    Delandistrogene moxeparvovec

    go.drugbank.com/drugs/DB16802
    ApprovedInvestigational

    It was granted accelerated approval by the FDA on June 22, 2023, as the first gene therapy to treat Duchenne Muscular Dystrophy (DMD).

  10. Drug

    Tabelecleucel

    go.drugbank.com/drugs/DB17072
    ApprovedInvestigational

    [L43557] The FDA has granted tabelecleucel Breakthrough Therapy Designation for EBV-associated PTLD following allogeneic HCT.[L43562]